Eric White, MD, global clinical development lead for rheumatology and pulmonology at Boehringer Ingelheim Pharmaceuticals

AI CT Tool for Early Pulmonary Fibrosis Detection Enters Phase 3, With Eric White, MD

Brainomix announced on January 20, 2026, that Boehringer Ingelheim has selected them to provide quantitative, automated high-resolution CT (HRCT) imaging biomarkers as a co-primary endpoint in the Phase 3 DROP-FPF study.

Early identification remains one of the most persistent challenges in interstitial lung disease and 

, where patients are often diagnosed after irreversible lung damage has already occurred. DROP-FPF aims to shift that paradigm by studying whether intervening earlier with nerandomilast, before symptoms and measurable lung function decline, can meaningfully alter the disease trajectory.

, Eric White, MD, global clinical development lead for rheumatology and pulmonology at Boehringer Ingelheim Pharmaceuticals, emphasized the unmet need this trial addresses.

“That there are no approved options for these individuals, and quite honestly, we're not entirely certain what to do with them,” White said. “When we see them, we tell them, ‘you might have something there, and it might turn into a disease later on,’ but we can't give them much more than that, and so this is one of the first studies to let us start to understand what that aspect of the disease, the very, very, very early disease, how that behaves, and whether intervention with a known, effective medication will improve their outcomes.”

DROP-FPF is a phase 3b randomized, placebo-controlled trial evaluating the safety and effectiveness of nerandomilast (Jascayd) in individuals with interstitial lung abnormalities and a family history of pulmonary fibrosis. A defining feature of DROP-FPF is its use of automated, quantitative high-resolution CT (HRCT) imaging biomarkers as a co-primary endpoint, which is the first phase 3 interstitial lung disease trial to do so.

White noted that imaging changes typically precede declines in forced vital capacity (FVC), the standard physiologic endpoint used in pulmonary fibrosis trials. As therapies improve and FVC decline becomes more modest, relying on lung function alone may no longer be sufficient to detect meaningful treatment effects.

“The nice thing about using a quantitative HRCT is that the computers can see changes in the images well before the human eye can,” White said.

The trial will use Brainomix’s FDA-cleared e-Lung platform to quantify metrics, including the reticular vascular score and total disease extent, providing a granular view of early structural changes. White pointed to growing evidence that quantitative CT changes predict lung function decline, mortality, and overall outcomes, supporting their clinical relevance.

DROP-FPF will enroll approximately 80 participants using a rolling enrollment design, with each individual followed for ≥ 2 years. Beyond imaging progression, investigators will track symptom development, including cough, dyspnea, and fatigue, to better define when early interstitial lung disease becomes clinically apparent. Although the study is not expected to change practice immediately, White said it could provide critical evidence supporting earlier identification, closer monitoring, and earlier intervention, laying the groundwork for a more proactive approach to pulmonary fibrosis care.

“We also think [using a quantitative HRCT is] important because, as more and more drugs come to market for treating patients with pulmonary fibrosis, our ability to [detect] the change over time in breathing tests and forced vital capacity is diminishing, so it's going to be harder to determine whether a drug is doing something for a patient purely based on the forced vital capacity,” White said. “The imaging study will show us what parts of the lungs are being destroyed before it impacts the amount of volume that comes out. Because of that, the imaging should give us quite a bit of information before we even get to the point where people are starting to lose lung volumes.”

Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis. PR Newswire. Published on January 20, 2026. Accessed on February 5, 2026. 

https://www.prnewswire.com/news-releases/brainomix-e-lung-ai-imaging-technology-selected-as-co-primary-endpoint-in-boehringer-ingelheim-phase-3-clinical-trial-in-pulmonary-fibrosis-302664595.html

Videos

The DROP-FPF Phase 3b trial will use automated HRCT biomarkers to assess whether early treatment with nerandomilast can slow disease progression before lung function declines.


News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Pulmonary Fibrosis

Andrew Russman, DO, is a neurologist and the section head of stroke and vascular neurology at the Cleveland Clinic.

Asundexian Cuts Risk of Second Stroke - Results from OCEANIC-STROKE

Asundexian, an investigational oral Factor XIa (FXIa) inhibitor in development by Bayer, has shown its superiority to placebo in preventing 

 in patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA), based on results from the pivotal phase 3 OCEANIC-STROKE trial.

Despite a variety of treatment options, the risk of secondary stroke remains substantial – roughly 1 in 10 ischemic stroke survivors will experience another within 1 year, and 1 in 5 will have another stroke within 5 years. Secondary strokes are commonly more disabling and are associated with higher mortality and a greater risk of 

. Combining current strategies can reduce the risk of secondary stroke but has been associated with an increased bleeding risk.

“I think it’s really important to recognize that we’re always concerned that we’re adding bleeding risk,” Andrew Russman, DO, neurologist and section head of stroke and vascular neurology at the Cleveland Clinic, told 

 in an exclusive interview. “But that was not the case with asundexian in this study. Essentially, patients benefited from a reduction in their ischemic stroke risk without a concomitant increase in bleeding risk. And this is critically important.”

OCEANIC-STROKE was a multicenter, international, randomized, placebo-controlled, double-blind, parallel group, event-driven phase 3 study, conducted at 741 locations worldwide. Investigators enrolled patients who were ≥18 years old with acute non-cardioembolic stroke or high-risk TIA and systemic or cerebrovascular 

 or acute non-lacunar infarct. Patients were excluded if they had ischemic stroke ≤7 days before the index event, a history of atrial fibrillation or flutter, left ventricular thrombus, mechanic valve, or other cardioembolic source of stroke, among other criteria.

The study’s primary endpoints were time to first occurrence of ischemic stroke and time to first occurrence of International Society on Thrombosis and Hemostasis (ISTH) major bleeding, both up to 31 months. Secondary outcomes included time to first occurrence of ischemic and hemorrhagic strokes, time to first occurrence of a composite of cardiovascular death, myocardial infarction, or stroke, and time to first occurrence of all-cause mortality, among others.

A total of 12,327 patients were enrolled in the trial; of these, 43% had large-artery atherosclerosis, 23% had small-vessel occlusion, 30% had stroke of undetermined etiology, 3% had other etiology, and 2% had cardioembolic stroke. Patients were randomly assigned in a 1:1 ratio to receive either oral asundexian once daily or matching placebo.

Russman and colleagues found that asundexian reduced ischemic stroke by 26% (HR, 0.74; 95% CI, 0.65-0.84; 

 <.0001) with no increase in risk of ISTH major bleeding. This was consistent across all subgroups, including age, sex, index event, stroke subtype, National Institutes of Health Stroke Scale (NIHSS), and acute stroke therapy.

Secondary endpoints also showed that asundexian reduced ischemic and hemorrhagic stroke risk by 26% (6.6% vs 8.8%; HR, 0.74; 95% CI, 0.65-0.84; 

 <.0001) compared to placebo. Additionally, investigators saw no increase in the rate of ISTH major bleeding between asundexian and placebo (1.9% vs 1.7%; HR, 1.1; 95% CI, 0.85-1.44). The risk of bleeding was also similar compared to rates in the placebo arm.

“The benefit of the Factor XIa inhibitors is that they’re relatively selective; they act against the bad clot without harming the good clotting that’s part of healing,” Russman told 

. “Anticoagulants in general act against a variety of clotting, whether it’s the kind we need for healing or the bad kind of clotting that’s part of a pathologic process of a clot that could form and travel to the brain and cause a stroke.”

Asundexian has been granted Fast Track Designation by the 

Editor’s Note: Russman reports disclosures with Genentech, Medtronic, and Boston Scientific Corporation.

Bayer. Bayer’s asundexian demonstrated a substantial 26% reduction in stroke after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack, with no increase in ISTH major bleeding versus placebo. 

. February 5, 2026. Accessed February 5, 2026. 

https://www.businesswire.com/news/home/20260205888712/en/Bayers-Asundexian-Demonstrated-a-Substantial-26-Reduction-in-Stroke-After-a-Non-Cardioembolic-Ischemic-Stroke-or-High-Risk-Transient-Ischemic-Attack-With-No-Increase-in-ISTH-Major-Bleeding-Versus-Placebo

Sharma M. Factor XIa Inhibition With Asundexian in Acute Non-Cardioembolic Stroke or High-Risk Transient Ischemic Attack: Primary Results of the OCEANIC-STROKE Trial. Abstract presented at the American Stroke Association’s International Stroke Conference 2026. New Orleans, LA. February 4-6, 2026.

Bayer. A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke (OCEANIC-STROKE). ClinicalTrials.gov Identifier: NCT05686070. Updated November 11, 2025. Accessed February 5, 2026. 

https://clinicaltrials.gov/study/NCT05686070

Russman highlights asundexian’s efficacy in patients following a non-cardioembolic ischemic stroke or high-risk transient ischemic attack.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Strategic Alliance Partnership

OCEANIC-STROKE: Asundexian Reduces Stroke Risk Without Increasing Bleeding, With Andrew Russman, DO

How the 2025 KDIGO Guidelines Are Personalizing IgA Nephropathy Care, With Gerald Appel, MD

 and IgA vasculitis (IgAV), in tandem with the evolving therapeutic landscape, has introduced significant changes to clinical care, essentially individualizing treatment strategies.

These clinical shifts included a reassessment of treatment targets for key biomarkers and a greater emphasis on addressing the underlying mechanisms driving disease progression.

From a clinician's perspective, Gerald Appel, MD, professor of clinical medicine at Columbia University, IgAN has shifted management toward a more personalized approach, supported by a broader range of therapeutic options, combination strategies, and long-term patient-centered goals.

In practice, this personalization is increasingly guided by biopsy findings, baseline proteinuria, and patient-specific risk factors, allowing clinicians to tailor therapy based on dominant inflammatory or hemodynamic drivers of disease.

“Kidney biopsy can be very helpful in this regard. If a patient has significant scarring, therapy may focus more on ACE inhibitors, ARBs, endothelin receptor antagonists, and SGLT2 inhibitors,” said Appel.” If inflammation predominates, we may target that pathway more aggressively.”

Notably, the 2025 KDIGO IgAN guideline encourages kidney biopsy in adults with suspected IgAN and proteinuria ≥0.5 g/d. This represents a shift from the 2021 guideline, which emphasized reducing proteinuria to <1 g/d.

Additionally, the guideline authors underscore proteinuria as a validated surrogate marker for long-term renal outcomes, supporting both earlier diagnostic evaluation and more aggressive treatment targets. The updated guideline reduces the recommended target to <0.5 g/d, with an ideal goal of <0.3 g/d, regardless of treatment status, reflecting evidence linking persistent proteinuria to an increased lifetime risk of kidney failure.

A major new concept in the 2025 guideline is to initiate treatment with therapies to prevent or reduce pathogenic IgA production and IgA/IgA and IgA/IgG immune complex formation, along with therapies to manage the consequences of existing IgAN-induced nephron loss.

“For example, targeted-release budesonide (Tarpeyo) acts on the distal ileum, specifically the Peyer’s patches, where it reduces the production of galactose-deficient IgA1 and immune complexes. This, in turn, reduces proteinuria and kidney injury,” explained Appel. “Other emerging agents also block the production of galactose-deficient IgA1 and immune complexes, while some newer therapies primarily focus on reducing proteinuria and inflammation. We now have multiple points of intervention to alter the course of the disease, and KDIGO highlights this approach.”

The 2025 KDIGO recommendations emerge amid a rapidly evolving IgAN therapeutic landscape, with 10 agents in late-phase clinical development demonstrating comparable proteinuria reductions. These late-phase programs span multiple mechanistic classes, including endothelin pathway inhibition, complement modulation, and targeted immunosuppression, reinforcing the guideline’s emphasis on combination and mechanism-driven therapy.

Collectively, these advances have the potential to expand clinician choice and create new opportunities to individualize disease management.

As therapeutic options continue to expand, the 2025 KDIGO guideline provides a framework for integrating emerging agents into individualized treatment strategies aimed at delaying or preventing kidney failure.

Editor’s Note: Appel reports relevant disclosures with Novartis, Travere Therapeutics, and others. 

Floege J, Barratt J, Cook HT, et al. Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). 

https://doi.org/10.1016/j.kint.2025.04.003

Jürgen Floege, MD. PREVAIL: Felzartamab’s Sustained Clinical Outcomes In IgAN, With Jurgen Floege, MD. HCPlive

 Published online November 20, 2025. doi:

https://doi.org/10.1016/S0140%E2%80%916736(23)02302%E2%80%914

Brooks A. KDIGO Releases Updated IgA Nephropathy, IgA Vasculitis Clinical Practice Guideline. HCPLive. Published September 18, 2025. Accessed February 5, 2026. 

https://www.hcplive.com/view/kdigo-releases-updated-iga-nephropathy-iga-vasculitis-clinical-practice-guideline

2025 KDIGO guidelines reshape IgA nephropathy care with earlier biopsy, tighter proteinuria targets, and personalized treatment strategies.


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Susanne Brix Pedersen, professor at DTU Bioengineering

Early-Life Gut Bacteria Linked to Lower Food Allergy Risk, With Susanne Pedersen

Vaginal delivery, exclusive breastfeeding, and early exposure to siblings emerged as the strongest drivers of colonization with allergy-protective gut bacteria in infancy, offering clinicians a concrete context for how early-life exposures may shape long-term immune risk.

“What we see is that it seems to be very important for the early colonization with these aromatic lactate-producing bifidobacterial that that that you deliver naturally so by vaginal birth,” Susanne Brix Pedersen, a professor at Technical University of Denmark (DTU) Bioengineering, told 

“You can, of course, also introduce these bacteria to a cesarean section-born infant by giving a slurry of the fecal matter from the mother. [It] has been done in a few…studies conducted in the US.”

In a recent longitudinal study, investigators showed that infants colonized early with aromatic lactate–producing bifidobacteria were significantly less likely to develop 

food allergen–specific immunoglobulin E (IgE)

 and atopic dermatitis in childhood. The findings extend earlier work linking the infant gut microbiome to immune tolerance and help clarify which perinatal factors most strongly influence the acquisition of these beneficial microbes.

The study followed 147 children born in Sweden between 2003 and 2005, with fecal samples collected at 8 time points from birth through age 5 years, alongside maternal samples, blood draws, and clinical follow-up. Using genetic and metabolomic profiling, investigators identified a subset of bifidobacteria capable of converting aromatic amino acids into aromatic lactates. Infants with high abundance of these bacteria, particularly during the first 6 months of life, had elevated gut levels of aromatic lactates and a reduced risk of food allergen–specific IgE through 5 years old, as well as lower rates of atopic dermatitis at 2 years old.

Among early-life exposures, vaginal delivery had the most pronounced effect. Infants born vaginally were approximately 14 times more likely to be colonized with these bifidobacteria than those born by cesarean section.

Exclusive breastfeeding during the first 2 months of life also strongly promoted colonization, while early formula supplementation was associated with markedly lower bacterial abundance. Having older siblings further increased the likelihood of early colonization, suggesting a role for household microbial exposure.

Mechanistically, the protective association was mediated by 4-hydroxy-phenyllactate (4-OH-PLA), a bacterial metabolite that selectively inhibited IgE—but not IgG—production in ex vivo human immune cell cultures.

“It's quite important that you…don't see an inhibition of the IgG because the IgG is there to protect us against the different infections that we are acquiring during early life,” Pedersen said. “If we see an increase…or a decrease of that…that might have had some implications in terms of infection burden. Having a selective inhibition of the IgE, which is so IGE is connected to allergic diseases, but also, of course, to the ability of handling a parasite infection. In this case, we didn't see a total IGE inhibition, but an anti-allergen specific IGE inhibition.”

The findings point toward multiple potential prevention strategies, including supporting bifidobacterial growth through breastfeeding-associated substrates, targeted probiotic supplementation in infants with low colonization, or direct delivery of aromatic lactates. For clinicians, the results reinforce the importance of early-life counseling while underscoring that microbiome-based interventions are not yet ready for routine practice.

“[The next step] is actually to convene on these intervention studies to make sure that supplementation to, for instance, C-section born infants, would provide them with the right colonizing bifidobacteria in the early life,” Pedersen said.

Myers PN, Dehli RK, Mie A, et al. Early-life colonization by aromatic-lactate-producing bifidobacteria lowers the risk of allergic sensitization. 

Pedersen S. Early-Life Bifidobacteria Linked to Lower Food Allergy Risk, With Susanne Brix Pedersen. Published on February 4, 2026. Accessed on February 5, 2026. 

https://www.hcplive.com/view/early-life-bifidobacteria-linked-lower-food-allergy-risk-susanne-brix-pedersen

Vaginal delivery, exclusive breastfeeding, and early sibling exposure strongly predicted colonization with bifidobacteria that suppress IgE responses in a recent study.


Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Giles W. Story, PhD, from the University College London

Delay discounting did not predict relapse after antidepressant discontinuation in patients with remitted 

 despite a modest association with residual depressive symptoms, new data show.

, of University College London, noted that the findings highlight the lack of reliable tools for predicting MDD relapse and emphasize the importance of individualized, shared decision-making when counseling patients.

The multi-site longitudinal study, led by Story and Doron Elad, PhD, of Technion-Israel Institute of Technology, enrolled 97 patients with remitted MDD receiving antidepressants and 54 matched healthy controls across Zurich and Berlin, with participants completing validated delay discounting tasks at baseline and after randomization to continuation or discontinuation. During the 6-month follow-up, 35% of patients relapsed. Patients with remitted MDD showed steeper baseline delay discounting than controls (Cohen’s d = 0.34), and a modest link to subthreshold depressive symptoms, but neither baseline discounting nor post-discontinuation changes predicted relapse.

During the interview, Story also addressed study limitations, including the relatively short follow-up period for a chronic, relapsing illness, and suggested future research may benefit from examining more dynamic, stress-responsive behavioral markers rather than relying on static, single-time-point measures.

 What should clinicians take away from the study when counseling patients who are considering continuing antidepressant medication?

 The decision to stop or come to the new antidepressant is a difficult one. It's one that has to be made on an individual basis, and [in] discussion with the clinician. In some ways, our study contributes to the uncertainty around that decision.

We know…that continuing an antidepressant actually reduces your risk of relapse. Amongst people…that stop [a] antidepressant, around 40% of those will go on to relapse. Those [who] continue it, around 20%...relapse. We know that [taking] an antidepressant reduces the risk of relapse, but this needs to be weighed against side effects and tolerability.

And of course, because we don't know for any given person whether or not stopping the medication is going to be the thing that makes the difference. It’s something that has to be thought about in context…where that person is in their life, or other treatment options. They might have [to] start some talking therapy…My advice would be that's something to think through and communicate with [a] clinician.

 Can you discuss the limitations of the study?

 It was a fairly short follow-up time. Patients were followed up for 6 months… whereas depression is a chronic illness that can relapse over some years. It may be that if you had a very long follow-up, you'd start to fix some of these effects. That said, we had a reasonable number relapsing even in [a] not short time.

There was some dropout. Some people were lost [to] follow up, [which could] potentially… mean we missed an effect. Let's say, for example, that more impulsive people were more likely to relapse and they're more likely to drop out. That might mean that we can miss [a] bunch of important signals.

 Were there any subgroups in whom delay discounting may still have clinical relevance?

 In this particular study, we didn't do much on the way of subgroup analysis, but we do know from other work that discounting is quite strongly associated with addiction dependence.

This is an area where discounting can have some migrants. [It] is probably the strongest of all clinical syndromes that are linked to discounting. And there’s actually some evidence of prospective prediction as well. For example…a study that measured people's discounting as they went into a bar…found that people [who] were more impatient for reward as they were entering the bar became more drunk than higher blood patients.

 How might future studies build on this work to identify more reliable behavior or cognitive prediction predictors of relapse?

 I think we need to move to more dynamic forms of prediction. Relapse is a complex thing and depends on that interaction between a person, their social world, and the outside world. It might be more fruitful to start to look at stress test markers. For example…how somebody's discounting changed in response to a change in their circumstances might be more powerful than discounting as a standalone.

Elad D, Story GW, Berwian IM, Stephan KE, Walter H, Huys QJM. Delay discounting correlates with depression but does not predict relapse after antidepressant discontinuation. Mol Psychiatry. Published online January 8, 2026. 

Story G. Delay Discounting vs Traditional Predictors of MDD Relapse, With Giles Story, PhD. HCPLive. Published on February 1, 2026. Accessed on February 4, 2026. 

https://www.hcplive.com/view/delay-discounting-vs-traditional-predictors-mdd-relapse-giles-story-phd

Story G. Delay Discounting Offers No Predictive Value for MDD Relapse, With Giles Story, PhD. HCPLive. Published on February 4, 2026. Accessed on February 4, 2026. 

https://www.hcplive.com/view/delay-discounting-offers-no-predictive-value-mdd-relapse-giles-story-phd

Articles

New study shows baseline impulsivity links to residual symptoms but not relapse, highlighting the need for individualized, clinician-guided decisions.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

Viet Le, DMSc, PA-C, is a preventive cardiology PA at Intermountain Health and the former president of the Academy of Physician Associates in Cardiology.

In the final segment, experts discuss how to navigate traditional or cultural foods with patients in the absence of their inclusion in the guidelines.

Special Reports

Cultural Diversity, Personalization, and Meeting Patients Where They Are

In part 7 of the discussion, experts reflect on access issues regarding foods recommended in the guidelines.

Food Access, Equity, and Removing Shame From Nutrition Guidance

Part 6 of the discussion takes a closer look at added sugar recommendations from the guidelines and scenarios where individualization may be needed.

Navigating Added Sugar Recommendations Across Different Age Groups and Clinical Contexts

In part 5 of the discussion, the panel examines gaps within the pediatric sections of the updated dietary guidelines.

Pediatric Gaps in the Dietary Guidelines

In part 4 of the discussion, experts review notable omissions and oversights in the guidelines, including fiber, whole grains, and plant-based foods.

Fiber, Whole Grains, and Other Gaps in the 2025–2030 Guidelines

In part 3 of this discussion, experts break down saturated fat recommendations and why visuals in the guidelines may cause confusion.

Interpreting Saturated Fat Recommendations

In part 2 of the discussion, experts discuss recommendations around protein intake, including controversy and misconceptions.

Quantity, Quality, and the Risk of Misinterpreting the Message Around Protein

In the opening segment of this special report, a trio of experts discuss what's new in the 2025-2030 Dietary Guidelines.

Reframing the Dietary Guidelines: Whole Foods, the Microbiome, and a Shift Toward the Consumer

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

This secondary analysis of the phase 3b SOUL cardiovascular outcomes trial indicates oral semaglutide’s potential capacity to reduce HF events.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Oral Semaglutide May Reduce Heart Failure Risk in Patients With T2D

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Podcasts

Reau and Brown are joined by Amanda Van Jacobs, MS, RDN, and Jessica Mellinger, MD, to discuss the new dietary guidelines through the lens of liver health.

Hepatology

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Liver Lineup: Updates & Unfiltered Insights

Introducing Liver Lineup: Updates & Unfiltered Insights — an exciting new podcast delivering timely, candid perspectives on the most pressing topics in the fast-moving world of hepatology. Created by Nancy Reau, MD, and Kimberly Brown, MD, and hosted by HCPLive, this series dives into the cutting edge of liver disease research, clinical care, and real-world practice.

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Latest News

AI CT Tool for Early Pulmonary Fibrosis Detection Enters Phase 3, With Eric White, MD

OCEANIC-STROKE: Asundexian Reduces Stroke Risk Without Increasing Bleeding, With Andrew Russman, DO

How the 2025 KDIGO Guidelines Are Personalizing IgA Nephropathy Care, With Gerald Appel, MD

Early-Life Gut Bacteria Linked to Lower Food Allergy Risk, With Susanne Pedersen

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD